Brg1-dependent epigenetic control of vascular smooth muscle cell proliferation by hydrogen sulfide  by Li, Li et al.
Biochimica et Biophysica Acta 1833 (2013) 1347–1355
Contents lists available at SciVerse ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbamcrBrg1-dependent epigenetic control of vascular smooth muscle cell
proliferation by hydrogen sulﬁdeLi Li a,1, Die Liu a,1, Dingfang Bu b, Stella Chen c, Jianxin Wu d, Chaoshu Tang e,f,⁎,
Junbao Du a,f,⁎⁎, Hongfang Jin a,⁎⁎⁎
a Department of Pediatrics, Peking University First Hospital, Beijing 100034, PR China
b Central Laboratory, Peking University First Hospital, Beijing 100034, PR China
c Department of Biochemistry and Cellular Biology, University of California, San Diego, La Jolla, CA, USA
d Central Laboratory, Capital Institute of Pediatric Research, Beijing 100020, PR China
e Department of Physiology and Pathophysiology, Peking University Health Science Center, Beijing 100191, PR China
f Key Laboratory of Molecular Cardiology, Ministry of Education, Beijing 100191, PR ChinaAbbreviations: VSMCs, vascular smooth muscle cel
cystathionine γ-lyase; CBS, cystathionine β-synthase; M
tein kinase; Brg1, Brahma-related gene 1; Brm, Brah
RASMCs, rat aortic smooth muscle cells; DMEM, Dulbec
FBS, fetal bovine serum; CCK-8, cell counting kit-8; NaH
endothelin-1; Pdgfα, platelet-derived growth factor su
Pcna, proliferating cell nuclear antigen; HSs, hypersensi
munoprecipitation; Erk, extracellular signal-regulated ki
tor; MRTFA, myocardin-related transcription factor A
⁎ Correspondence to: C. Tang, Department of Physiolo
University Health Science Center, Beijing 100083, PR Chin
⁎⁎ Correspondence to: J. Du, Department of Pediatrics, P
Xi-AnMen Str. No. 1, West District, Beijing 100034, PR C
fax: +86 10 66530532.
⁎⁎⁎ Correspondence to: H. Jin, Department of Pediatrics,
Xi-AnMen Str. No. 1, West District, Beijing 100034, PR C
fax: +86 10 66530532.
E-mail addresses: tangchaoshu@263.net.cn (C. Tang
jinhongfang51@126.com (H. Jin).
1 They contributed equally to this work.
0167-4889/$ – see front matter © 2013 Elsevier B.V. All
http://dx.doi.org/10.1016/j.bbamcr.2013.03.002a b s t r a c ta r t i c l e i n f oArticle history:
Received 6 December 2012
Received in revised form 2 March 2013
Accepted 3 March 2013
Available online 13 March 2013
Keywords:
Brg1
Epigenetic
Hydrogen sulﬁde
Vascular smooth muscle cells
ProliferationHydrogen sulﬁde (H2S) canmodulate the proliferation of vascular smoothmuscle cells. This study was designed
to investigate the epigenetic control of vascular smooth muscle cell proliferation in response to H2S. Microarray
analysis indicated that Brahma-related gene 1 (Brg1) and proliferation-related genes including proliferating cell
nuclear antigen (Pcna), neurotrophin 3 (Ntf3) and platelet-derived growth factor subunit A (Pdgfα) were signif-
icantly downregulated by H2S in endothelin-1-stimulated proliferative vascular smooth muscle cells. Brg1 is the
central catalytic subunit of the SWI/SNF apparatus (an ATP-dependent chromatin remodeling complex).
Overexpression and knockdown of Brg1 conﬁrmed that Brg1 was crucial for H2S-induced inhibition of vas-
cular smoothmuscle cell proliferation. A luciferase reporter assay, real-time PCR andWestern blotting dem-
onstrated that H2S inhibited Brg1 transcription and expression. A DNase I hypersensitivity assay revealed
that H2S reversed endothelin-1-stimulated Pcna, Ntf3 and Pdgfα chromatin remodeling and vascular smooth
muscle cell proliferation. A chromatin immunoprecipitation assay indicated that H2S inhibited the recruitment
of Brg1 to the Pcna,Ntf3 and Pdgfα promoters. The results of this study indicate that H2S inhibits vascular smooth
muscle cell proliferation via an epigenetic mechanism involving the inhibition of Brg1 transcription and expres-
sion, and by reducing the recruitment of Brg1 to the Pcna, Ntf3 and Pdgfα promoter regions.
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Vascular structural remodeling is one of the most important path-
ophysiological processes in a variety of vascular diseases. In normal
vascular tissues, vascular smooth muscle cells (VSMCs), the major
component of the medial layer of arterial walls, are quiescent. However,
VSMCs undergo a phenotypic transition in response to hemodynamic,
neuronal or hormonal stimuli, leading to VSMC hypertrophy, prolifera-
tion,migration and invasion,which eventually results in vascular remod-
eling [1–3].
The ﬁndings of gaseous signals substantially promoted the de-
velopment of biomedical science [4,5]. Hydrogen sulﬁde (H2S) was
found to be produced endogenously in the cardiovascular system
from the sulfur-containing amino acid cysteine by the key metabolic
enzymes cystathionine γ-lyase (CSE), cystathionine β-synthase (CBS)
and 3-mercaptosulfurtransferase [6,7]. There is evidence that the
gasotransmitter H2S exerts a wide range of actions in the cardiovas-
cular system [7–10]. For instance, H2S plays a fundamental role in the
proliferation and survival of VSMCs via the mitogen-activated pro-
tein kinase (MAPK) pathway [11,12].
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of multicellular eukaryotes are expressed in a spatially and temporally
controlled fashion [13,14]. Epigenetic alterations do not involve changes
in the sequence of nucleotide base pairs or the dosage or arrangement of
genes, rather they involve chemical alterations to the genome that
modulate gene expression [13]. Chromatin-remodeling proteins have
been shown to alter local chromatin structure and facilitate recruitment
of the essential factors required for transcription. Alteration of chromatin
architecture by ATP-dependent remodeling complexes is considered to
be a signiﬁcant step in the transcriptional regulation of many eukaryotic
genes. The SWI/SNF complex, a type of large molecular weight ATP-
dependent remodeling complex, regulates the transcriptional activity
of many genes by altering the chromatin structure around the genes
[15,16]. The protein encoded by Brahma-related gene 1 (Brg1), which
possesses helicase and ATPase activities, is the central catalytic subunit
of the SWI/SNF apparatus, and thus it uses the energy derived from hy-
drolysis of ATP to disrupt the chromatin architecture of target pro-
moters [17–21]. The SWI/SNF complex is associated with the control
of cellular proliferation and differentiation, and exerts regulatory effects
on the cell cycle [22,23]. Compared to Brahma (Brm), another impor-
tant subunit of the SWI/SNF complex, Brg1 plays a more crucial role in
vascular tissue and cell survival. For example, Brg1 is necessary for
myocardin-induced expression of smooth muscle-speciﬁc genes and
plays a pivotal role in the vascular development ofmammalian embryos
[24,25]. Knockout of Brg1 in the cardiovascular systemof newbornmice
was reported to result in fatal cardiopulmonary abnormalities and a
severe lack of contractile proteins in VSMCs [24,26]. Furthermore, it
was proven that RNA interference (RNAi)-mediated knockdown of
Brg1 induced p53 activation and cell cycle arrest in vitro [27].
As H2S can affect cellular proliferation and survival, processes which
are tightly regulated by epigenetic mechanisms, we hypothesized that
H2S may regulate VSMC proliferation via an epigenetic mechanism.
Therefore, in the present study, we aimed to investigate the possible
epigeneticmechanisms bywhichH2Smodulates chromatin remodeling
and the expression of target genes to inhibit VSMC proliferation.
2. Methods
2.1. Culture of rat VSMCs
Primary rat aortic smooth muscle cells (RASMCs) were obtained
from explant culture of aortic tissue from adult Sprague–Dawley rats
and used between passages 4 and 8. Rat A7r5 VSMCs were obtained
from the American Type Culture Collection (ATCC CRL 1444; Manassas,
VA, USA) at passage 11 and used at passages 13 to 22. Cells were cul-
tured in Dulbecco's modiﬁed Eagle's medium (DMEM) containing 10%
fetal bovine serum (FBS) and 2 mmol/L glutamine in an atmosphere
of 5% CO2 at 37 °C.
2.2. Evaluation of the viability and proliferation of VSMCs by the WST-1
and Cell counting kit-8 (CCK-8) assays
The viability and proliferation of RASMCs were evaluated using
the WST-1 assay (BioVision Research Products, Milpitas, CA, USA).
Brieﬂy, 1 × 103 cells/well were incubated in 96-well plates overnight,
starved in serum-free medium for 24 h, and treated with 10−3 mol/L
sodium hydrosulﬁde (NaHS) or 10−4 mol/L NaHS for 24 h, 48 h and
72 h, incubated with 10 μL of WST-1 reagent for 45 min and absor-
bancewasmeasured at 450 nmusing amicroplate reader (BioRad, Her-
cules, CA, USA). In addition, the same number of RASMCs was starved,
treated with 10−7 mol/L endothelin-1 (ET-1) and/or 10−4 mol/L
NaHS for the indicated times and subjected to the WST-1 assay. The
CCK-8 assay was used after the transfection experiments. A7r5 VSMCs
were incubated with 10 μL of CCK-8 solution for 1 h and absorbance
was measured at 450 nm using a microplate reader (BioRad).2.3. Flow cytometry
RASMCs, untreated and treated with 10−7 mol/L ET-1 and/or
10−4 mol/L NaHS for 72 h, were harvested and ﬁxed in 70% ethanol
overnight at −20 °C. The cells were pelleted, re-suspended in PBS
containing 100 μg/mL RNase A at 37 °C for 30 min, stained with
50 μg/mL propidium iodide for 10 min, and then cell cycle and late
apoptosis were analyzed by ﬂow cytometry (Becton-Dickinson, Franklin
Lakes, NJ, USA). Results are expressed as percentage of cells for cell cycle
analysis and for late apoptotic phase cells distinguished from live cells.2.4. Microarray assay
RASMCs treated with 10−7 mol/L ET-1 and/or 10−4 mol/L NaHS
for 72 h were assayed independently three times. Total RNA was
extracted using TRIzol (Invitrogen, Carlsbad, CA, USA) or the RNeasy
kit (Qiagen, Germantown, MD, USA), ampliﬁed, labeled using the
Quick Amp Labeling kit (Agilent Technologies, Santa Clara, CA, USA),
and then hybridized to the Whole Rat Genome Microarray Kit 44K
(Agilent Technologies) in Agilent SureHyb Hybridization Chambers.
After hybridization and washing, the slides were scanned using a DNA
microarray scanner, and data extracted from Agilent Feature Extraction
Software (version 10.5.1.1) were imported into the Agilent GeneSpring
GX software (version10.0) for further analysis. The 6 microarray data
sets were normalized in GeneSpring GX using the Agilent FE one-color
scenario (mainly median normalization). Genes marked ‘present’ or
‘marginal’ in all samples were chosen for analyses. The Student's t-test
was used to identify the differentially expressed genes. Candidate genes
were analyzed using GEArray-Analyzer (http://www.ncbi.nlm.nih.gov/),
Bio Associations Index (http://www.pubgene.org/) and DAVID
Functional Annotation Bioinformatics Microarray Analysis (http://
david.abcc.ncifcrf.gov/), and then selected on the basis of an expres-
sion change > 1.5-fold and a paired t-test value of P b 0.05.2.5. Quantitative real-time PCR
Total RNA isolated from RASMCs treated with 10−7 mol/L ET-1
and/or 10−4 mol/L NaHS for 72 h was reverse-transcribed using an
oligo d(T)18 primer and M-MLV reverse transcriptase. PCR primers
were designed for ampliﬁcation of the rat platelet-derived growth fac-
tor subunit A (Pdgfα), neurotrophin 3 (Ntf3), proliferating cell nuclear
antigen (Pcna), Brg1 and GAPDH cDNAs by quantitative real-time PCR
using SYBR Premix Ex Taq (ABI, Carlsbad, CA, USA). The relative expres-
sion of the target mRNAs in each sample was normalized to GAPDH
(Supplementary Table 1).2.6. Western blotting analysis
Cultured RASMCs (3 × 106), treated with 10−7 mol/L ET-1 and/or
10−4 mol/L NaHS for 72 h, were harvested and lysed in lysis buffer
(0.5 mmol/L EDTA, 10 mmol/L Tris–HCl, pH 7.4, 0.3 mol/L sucrose,
and protease inhibitor cocktail). Protein extracts were separated on
SDS-PAGE gels and transferred onto nitrocellulose membranes. The
primary antibodies anti-Pcna (Santa Cruz Biotechnology, Santa Cruz,
CA, USA), anti-Pdgfα (Santa Cruz Biotechnology), anti-Ntf3 antibody
(Abcam, Cambridge, MA, USA), anti-BRG1 (Abcam), anti-phospho-
Erk1/2 (Cell Signaling Technology, Danvers, MA, USA), anti-Erk1/2
(Kangcheng, Shanghai, China), anti-GAPDH (Kangcheng, Shanghai,
China), and anti-β-actin (Santa Cruz Biotechnology) were used,
followed by a horseradish peroxidase-conjugated secondary antibody
(Santa Cruz Biotechnology); the bands were visualized using enhanced
chemiluminescence. The density of the positive bands was determined
using a Kodak X-Omat Blue XB-1 (Rochester, NY, USA).
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DNase I hypersensitive sites (HSs) are regions sensitive to cleavage
by DNase I, which indicates the location of regulatory regions and
locus control regions; HSs can represent the transcriptional activities
of these sequences [28,29]. We designed primers (each primer pair
covered a 200–400 bp sequence) for the regulatory regions, especially
the promoters, of the Pcna, Pdgfα, and Ntf3 genes to identify DNase I
HSs (Supplementary Table 2).
A7r5 cells, untreated and treated with 10−7 mol/L ET-1 and/or
10−4 mol/L NaHS for 72 h, were washed in PBS, pelleted, re-suspended
in RSB buffer (20 mmol/L Tris–HCl, pH 7.4, 10 mmol/L KCl, 1.5 mmol/L
MgCl2, 1 mmol/L CaCl2, 0.5% NP-40, 100 μg/mL PMSF and 20 μg/mL
RNase A), and homogenized using a Dounce homogenizer (Wheaton,
Millville, NJ, USA). Cell lysates were divided into ﬁve aliquots of
25 μL/tube and digested with 0, 1, 2, 4 or 8 U of DNase I at 37 °C for
3 min, and the reactions were terminated by adding equal volumes
of stop buffer (0.1 mol/L NaCl, 0.1% SDS, 50 mmol/L Tris–HCl pH 8.0
and 100 mmol/L EDTA). After DNase I digestion, the samples were
treated with 50 μg/mL RNase A at 37 °C for 30 min and 50 μg/mL
proteinase K at 50 °C for 1 h, followed by DNA extraction by phenol/
chloroform and ethanol precipitation. The extractedDNA and untreated
genomic DNA samples were diluted to 2 ng/μL before amplifying the
DNase I HSs in the Pcna, Pdgfα, and Ntf3 genes by both conventional
PCR for showing products after gel electrophoresis and quantitative
real-time PCR using SYBR green for data analysis. The results were
expressed as the ratio of PCR products for the DNase I-digested samples
compared to the untreated genomic samples.
2.8. Chromatin immunoprecipitation (ChIP) assay
The ChIP assay was performed using the EZ ChIP™ kit (Millipore,
Billerica, MA, USA). A7r5 cells, untreated and treated with 10−7 mol/L
ET-1 and/or 10−4 mol/L NaHS for 72 h, were incubated with 1% formal-
dehyde for 10 min to crosslink DNA binding proteins in situ. The chro-
matin was sheared to 200–1000 bp by sonication, then the samples
were incubated with mouse anti-Brg1 antibody, non-speciﬁc mouse
IgG (negative control), anti-RNApolymerase II antibody (positive control)
or PBS (input control) at 4 °C overnight with shaking, and then diluted to
250 μgof chromatin/mL inChIPdilutionbuffer [30]. Immunoprecipitation
was carried out by adding 70 μL of protein G agarose to the mixture. The
antibodies/proteins/chromatin DNA complexes were eluted from the
protein G agarose beads. The puriﬁed input and ChIP DNA samples
were re-suspended in 60 μL of water for conventional PCR to amplify
the Pcna-HS1, Pdgfα-HS1 andNtf3-HS1 sites. The amounts of PCRproducts
were evaluated as the integrated density value of bands via AlphaEaseFC
(Alpha Innotech Corporation, San Leandro, CA, USA) after gel electro-
phoresis. The ChIP results were reported as ‘% input’ for each sample.
2.9. Functional evaluation of the Brg1 gene promoter using a luciferase
reporter gene assay
Two fragments of rat genomic DNA, Brg1 –573 to +219 (792 bp)
and Brg1 –681 to +219 (900 bp), were individually cloned into the
plasmid pGL3-basic (Promega, Madison, WI, USA) upstream of the
luciferase gene. The plasmid pGL3-basic was used as a negative con-
trol, pGL3-control as a positive control, and the plasmid pRL-SV40 as
an internal reference. VSMCs were plated into six-well plates at
3 × 105 cells/well for 1 day and then transfected with 700 ng of
pGL3-basic-BRG1-792 or pGL3-basic-BRG1-900/well mixed with 7 ng
of pRL-SV40/well using Lipofectamine 2000 (Invitrogen). At 12 h
post-transfection, the A7r5 cells were treated with ET-1 and/or NaHS
as described above, cultured for another 24 h, harvested in lysis buffer,
and luciferase activities were determined using the dual-luciferase
reporter assay system (Promega, Madison, WI, USA). Fireﬂy luciferaseactivity was normalized to Renilla luciferase activity in each sample.
Each value represents an average of three independent experiments.
2.10. Overexpression and knockdown of Brg1 in VSMCs
To overexpress Brg1, themammalian expression vector pCMV6-Entry
containing the full-length Rattus norvegicus Brg1 cDNA (constructed by
OriGene Technologies, Rockville, MD, USA) was transiently transfected
into VSMCs. RNAi-mediated knockdown of Brg1 was performed using
the vector pGFP-V-RS. The recombinant RNAi plasmids were designed
by OriGene Technologies, and contained a 29 mer shRNA targeting the
sequence TTGAGAACGCCAAGCAGGATGTGGACGAT, or a scrambled
negative control non-effective shRNA cassette (constructed by OriGene
Technologies, USA). A7r5 VSMCs were cultured in serum-free medium
for 24 h to synchronize the cell cycle, and then treated with Turbofect
transfection reagent or transfected with the plasmids using Turbofect
transfection reagent (ThermoFisher, Waltham, MA, USA). At 24 h
post-transfection, the cells were treated with 10−7 mol/L ET-1 and/or
10−4 mol/L NaHS for 24 h, and then harvested for Western blotting to
quantify the expression of Brg1, Pcna, Pdgfα, Ntf3, phosphor-Erk1/2
and Erk1/2, or for the CCK-8 assay to evaluate VSMC proliferation.
2.11. Statistical analysis
Data are presented as the mean ± SD. Statistical comparisons were
analyzed with SPSS 13.0 software (SPSS, Chicago, IL, USA) using two-
tailed paired t-tests or analysis of variance (ANOVA) followed by post-
hoc analysis (Newman–Keuls test). P b 0.05 was considered signiﬁcant.
3. Results
3.1. H2S inhibits ET-1-induced VSMC proliferation
The viability of RASMCs was reduced by 10−3 mol/L NaHS but un-
affected by 10−4 mol/L NaHS (Fig. 1A), which is close to the physio-
logical concentration of H2S in rat serum. Therefore, we evaluated
the effect of H2S on RASMC growth using 10−4 mol/L NaHS. NaHS
at 10−4 mol/L inhibited the increase in cell growth induced by ET-1
(P b 0.01) but had little or no effect in cells which had not been
pretreated with ET-1 (Fig. 1B). The WST-1 assay also showed that
NaHS treatment could decrease ET-1-induced RASMC proliferation in a
speciﬁc time course (Fig. 1C). Cell cycle analysis demonstrated that the
proportions of ET-1-treated cells and ET-1 + NaHS-cotreated cells in
the G0/G1 phase were 63.22 ± 3.57% and 73.88 ± 3.03% (P b 0.05), re-
spectively; and 18.91 ± 2.10% and 10.62 ± 2.29% (P b 0.05) of ET-1-
treated cells and ET-1 + NaHS-cotreated cells were in the S phase,
respectively. Hence, NaHS inhibited the G1→ S phase progression in
ET-1-treated cells (Fig. 1D), which did not result from increasing cell
apoptosis by NaHS (Fig. 1E).
3.2. Brg1, Pcna, Ntf3 and Pdgfα may be involved in the inhibition of
ET-1-induced VSMC proliferation by H2S
Using a microarray assay, we identiﬁed that 18 chromatin
modiﬁcation-related genes were upregulated or downregulated in
ET-1 + NaHS-cotreated RASMCs, compared with ET-1-treated group.
We reviewed the literature on these 18 genes via the Bio Associations
Index to identify their biological functions, and the results were
conﬁrmed using the DAVID Functional Annotation Bioinformatics Mi-
croarray Analysis tool. Among the 18 genes, three chromatin remodel-
ing complex-related genes were identiﬁed (Supplementary Table 3).
Brg1 is a major chromatin modiﬁcation gene, and was signiﬁcantly
downregulated (by 41.86%) in ET-1 + NaHS-cotreated VSMCs. Of the
eight subunits of the chromatin remodeling complex SWI/SNF [ARIDIA,
ARIDIB, BRG1 (SMARCA4), SMARCAC2, SMARCAD2, SMARCD3, ACTL6A
and ACTL6B] examined in the microarray, only Brg1 mRNA was
Fig. 1. Effect of ET-1 and/or NaHS on RASMC viability, proliferation and Brg1, Pcna, Pdgfα and Ntf3 expression. (A) Dose-dependent effect of H2S on RASMC proliferation in cells
treated with NaHS, **P b 0.01. (B) Inhibitory effect of H2S on ET-1-induced RASMC proliferation, **P b 0.01. (C) Inhibitory effect of H2S on proliferation in RASMCs treated with
ET-1 in the speciﬁc time course, **P b 0.01 compared with control, ##P b 0.01 compared with ET-1 group. (D) Effects of H2S on cell cycle progression in ET-1-stimulated RASMCs,
*P b 0.05 comparedwith control, **P b 0.01 comparedwith control, #P b 0.05 comparedwith ET-1 group. (E) Effects of H2S on late apoptosis in RASMCs. (F andG) Inhibitory effects of H2S
on Brg1mRNAand protein expression in ET-1-pretreated RASMCs, **P b 0.01. (H) Effects of H2S onNtf3, Pdgfα and PcnamRNAexpression in ET-1-stimulated RASMCs, **P b 0.01. (I and J)
Effects of H2S on Ntf3, Pdgfα and Pcna protein expression in ET-1-stimulated RASMCs, **P b 0.01. Data are presented as mean ± SD of three independent experiments (n = 3).
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group (Supplementary Table 4). Quantitative real-time PCR and
Western blotting conﬁrmed that Brg1 mRNA was downregulated
by 62.35% and Brg1 protein expression was reduced by 61.18% in
ET-1 + NaHS-cotreated cells, compared with ET-1-treated cells
(both P b 0.01; Fig. 1F and G), consistent with the microarray results.
The genes involved in the inhibitory effect of H2S on ET-1-induced
RASMC proliferation mainly function in the MAPK pathway [31]. To
further characterize the genes thatmight be involved in the inhibitory ef-
fect of H2S on ET-1-inducedVSMCproliferation,we selected sevenMAPK
pathway-related genes (Egf, Pcna, Ntf3, Bdnf, Fgf2, Pdgfα and Ngfb) from
the Bio Associations Index, based on their roles in proliferationmediated
via the MAPK pathway. Compared with ET-1-treated VSMCs, the mRNA
expression levels of Egf, Pcna, Ntf3, Bdnf, Fgf2, Pdgfα and NgfB decreased
by 42.20%, 41.86%, 38.27%, 31.03%, 29.08%, 16.67% and 1.96% in the
ET-1 + NaHS-cotreated group, respectively. The changes in mRNA ex-
pression levels of Pcna,Ntf3 and Pdgfαwere signiﬁcant (P b 0.05). There-
fore, we focused on the effect of H2S on the expression of the Pcna, Ntf3
and Pdgfα genes. Quantitative real-time PCR and Western blotting con-
ﬁrmed that the mRNA and protein expression levels of Pcna, Ntf3 and
Pdgfα were downregulated in ET-1 + NaHS-cotreated cells, compared
with ET-1-treated cells (all P b 0.01; Fig. 1H–J).
3.3. H2S inhibits VSMC proliferation by downregulating expression of
Brg1 as well as impeding the activation of MAPK pathway
To conﬁrm that the downregulation of Brg1 is crucial for the inhi-
bition of VSMC proliferation by H2S, we transfected A7r5 cells withthe plasmid pCMV6-Entry-Brg1 to transiently overexpress Brg1, or with
pGFP-V-RS-Brg1 to transiently knockdown Brg1 expression using RNAi,
then the cells were treated with or without ET-1 or NaHS (Fig. 2A–C).
Brg1 protein was expressed at high levels in the Brg1-overexpressing
group (P b 0.01), and effectively silenced in the Brg1-shRNA group
(P b 0.01). The proliferation of Brg1-overexpressing VSMCs was signiﬁ-
cantly increased, compared to the negative control group (P b 0.01),
accompanied by the increased expression of Pcna (P b 0.01), Ntf3
(P b 0.01) and Pdgfα (P b 0.05). However, NaHS could not inhibit
VSMC proliferation or the protein expression of Brg1, Pcna, Ntf3
and Pdgfα in the Brg1 overexpression group (Fig. 2A–C). Conversely,
VSMC proliferation and the protein expression levels of Pcna, Ntf3
and Pdgfα were all reduced in the Brg1-shRNA group, compared
with the scrambled control group (all P b 0.05), and H2S could not
further inhibit the expression of Pcna, Ntf3 and Pdgfα or VSMC prolifer-
ation in the Brg1-shRNA group. Furthermore, the changes in phosphor-
ylation of Erk1/2 showed the same trend as those in the protein
expression of Brg1, Pcna, Ntf3 and Pdgfα (Fig. 2A–C). These results indi-
cated that the downregulation of Brg1 is crucial for the inhibition of
VSMC proliferation viaMAPK pathway by H2S.
3.4. H2S reverses ET-1-induced chromatin remodeling of the Pcna, Ntf3
and Pdgfα genes in VSMCs
When a gene begins to be transcribed, proteins in the nucleosomes
of the related chromatin are altered. Transcription factors bind to the
chromatin, enabling the cleavage of several areas byDNase I.We carried
out a DNase I hypersensitivity assay to determine if H2S could reverse
Fig. 2. Effect of Brg1 overexpression or knockdown on Brg1, Pcna, Ntf3 and Pdgfα protein expression, Erk1/2 phosphorylation and VSMC proliferation. (A and B) Brg1, Pcna, Ntf3 and
Pdgfα protein expression and Erk1/2 phosphorylation after overexpression or knockdown of Brg1 in VSMCs treated with ET-1 and/or NaHS, *P b 0.05, **P b 0.01. (C) VSMC proliferation
after overexpression or knockdown of Brg1 in cells treated with ET-1 and/or NaHS, *P b 0.05, **P b 0.01. Data are presented as mean ± SD of three independent experiments (n = 3).
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in VSMCs. Pcna was activated in ET-1-treated cells, and three HSs
(at −578 to −375, –416 to −167 and −282 to −40 upstream of
exon 1) were identiﬁed. The Pcna gene was largely inactivated in
ET-1 + NaHS-cotreated cells (Fig. 3A–D), and the relative amounts
of HS1, HS2 and HS3 cleavage reduced signiﬁcantly (all P b 0.05), com-
pared with ET-1-treated cells. Pdgfα was activated in ET-1-treated cells,
and two of the ten tested HSs were identiﬁed (+725 to +963 in intron
1 downstream of exon 1, and +918 to +1138 in intron 1/exon 1). The
relative amounts of Pdgfα HS1 and HS2 uncleavage were increased by
1.67-fold and 2.21-fold in the ET-1 + NaHS-cotreated group, respective-
ly (both P b 0.05), compared with the ET-1-treated group (Fig. 3E–G).
Ntf3 was activated in ET-1-treated cells, and two HSs (+1424 to
+1703 in intron 1, and+1679 to+1871 in intron 1/exon 2)were iden-
tiﬁed. The gene was signiﬁcantly inactivated in ET-1 + NaHS-cotreated
cells (Fig. 3H–K), with the relative quantity of HS1 and HS2 cleavage de-
creasing obviously (both P b 0.05), compared with ET-1-treated cells.
The data indicated that H2S reversed ET-1-induced chromatin remodel-
ing of the Pcna, Ntf3 and Pdgfα genes in VSMCs.3.5. H2S diminished the recruitment of Brg1 to the Pcna, Pdgfα and Ntf3
genes in ET-1 + NaHS-cotreated cells
We carried out a ChIP assay and ampliﬁed the DNA samples using
primers for the Pcna-HS1, Pdgfα-HS1 and Ntf3-HS1 to evaluate the
amount of the chromatin remodeling complex SWI/SNF recruited to
the promoter regions of these genes (Fig. 4A–C). H2S diminished the
recruitment of the SWI/SNF complex to the promoter regions of the
Pcna, Pdgfα and Ntf3 genes in the ET-1 + NaHS-cotreated group,
compared with the ET-1-treated group (all P b 0.01).
3.6. H2S affects the promoter region of Brg1 in ET-1-stimulated VSMCs,
resulting in downregulation of Brg1
The mechanism underlying the downregulation of Brg1 expression
induced by H2S was determined using a luciferase reporter gene
assay. A pGL3-basic vector, containing a fragment of genomic DNA
located at −681 to +219 upstream of exon 1 in the Brg1 gene, was
transfected into A7r5 cells. Luciferase reporter activitywasmuch higher
Fig. 3. H2S alters the local chromatin structure of the Pcna, Pdgfα and Ntf3 genes. PCR products ampliﬁed from DNase I-treated genomic DNA and untreated genomic DNA, indicating
the presence of DNase I hypersensitive site(s) (HSs). The Y axis refers to the ratio of PCR products in the DNase I-digested samples compared to untreated samples. (A–D) HS-1,
HS-2 and HS-3 in Pcna, *P b 0.05. (E–G) HS-1 and HS-2 in Pdgfα, *P b 0.05. (H–K) HS-1, HS-2 and HS-3 in Ntf3, *P b 0.05. Data are presented as mean ± SD of three independent
experiments (n = 3).
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luciferase reporter activitywas 77.32% lower in ET-1 + NaHS-cotreated
cells compared to ET-1-treated cells (Fig. 4D). The results implied that
H2Smight affect the promoter region of Brg1 to inhibit the transcription
of this gene in VSMCs.
4. Discussion
H2S, previously recognized as a pollutant gas, has recently been
regarded as a novel gaseous signal transmitter [10]. Endogenous H2S
ismainly generated by themetabolismof L-cysteine via transsulfuration
catalyzed by CSE in the cardiovascular system. The normal H2S con-
centration in rat serum is 45.6 ± 14.2 μmol/L, measured with a sul-
ﬁde sensitive electrode [32]; while a recent research demonstrated
that the sulﬁde concentration in rat blood samples, determined by
reversed-phase ﬂuorescence high performance liquid chromatogra-
phy (a more sensitive method), was in the range of 0.4–0.9 μmol/L
[33]. It has been reported that H2S can regulate L-type calcium cur-
rents in cardiomyocytes, attenuate hyperhomocysteinemia-induced
cardiomyocytic endoplasmic reticulum stress, modulate pulmonary
artery collagen remodeling, and negatively modulate the beta-
adrenoceptor in ischemia-induced cardiac injury [34–38]. Deﬁciency
of CSE resulted in redox imbalance in VSMCs and disturbances to
MAPK-regulated VSMC proliferation [11,12,39]. Overexpression of CSE
could stimulate apoptosis by activating the extracellular signal-
regulated kinase (Erk) and p38 MAPK, upregulating p21Cip/WAK-1
and downregulating cyclin D1 to inhibit VSMC proliferation [12].
S-diclofenac, a novel molecule containing an H2S-releasing dithiol-
thionemoiety attached by an ester linkage to diclofenac, could stabilize
p53 and induce the expressions of downstream proteins, such as p21,
p53AIP1 and Bax, to repress VSMC proliferation [40]. There is also
evidence that 100 μmol/L H2S can interact with estrogen to inhibit
VSMC proliferation via the estrogen receptor α/cyclin D1 pathway
[41]. Therefore, the H2S/CSE pathway exerts important physiologicaland pathophysiological functions to maintain vascular homeostasis.
Based on a previous investigation [11], the present study indicated that
H2S could also suppress VSMC proliferation by inducing cell cycle arrest.
Transcriptional, translational and post-transcriptional regulations
are required for the control of gene expression. Transcriptional control
is an important step of regulation. The DNA must be accessible to RNA
polymerase and the assortment of proteins which assist with the initia-
tion of transcription. Therefore, the chromosomal organization must be
‘open’ to the transcriptional apparatus, in order to be transcribed. The
alterations which occur to the nucleosomes in preparation for tran-
scription are termed ‘chromatin remodeling’ [42]. The ATP-dependent
chromatin remodeling complex can be grouped into four subfamilies
depending on their associated ATPase: SWI/SNF [mammalian Brm
(SNF2α) and Brg1 (SNF2β)], imitation switch (ISWI), Mi-2 (CHD1) and
INO80/SWR1 [43,44]. Chromatin remodeling in mammalian cells is
accomplished, at least in part, by ATPase-containing complexes from
the SWI/SNF family, which contain Brg1 or Brm as the central ATPase
subunit [45]. Brg1, as a central catalytic subunit of SWI/SNF, can regulate
the transcriptional activity of distinct genes [46–51]. Hence, Brg1may be
recruited to gene-speciﬁc promoters through direct or indirect interac-
tions involving one or more Brg1/hBrm-associated factor proteins. Brg1,
as a transcriptional co-regulator (co-activator or co-repressor), can induce
gene expression or inhibit transcription, and participates in the recruit-
ment and dynamic interactions with chromatin, which enables the
spatiotemporal regulation of a variety of geneswhich play roles in a num-
ber of cellular processes, including proliferation, apoptosis and differenti-
ation [48,52].
In the present study, microarray analysis demonstrated that, of the
eight subunits of the SWI/SNF complex, only Brg1 was differentially
expressed in VSMCs after NaHS treatment. The mammalian SWI/SNF
complex is closely related to cellular differentiation and proliferation,
and cooperation between Brg1 or Brm and p105Rb, an important cell
cycle regulator, successivelymodulates the activation of the transcription
factor, E2F [23,53,54]. Unlike Brm-deﬁcient mice, heterozygous Brg1 null
Fig. 4. H2S reduces the recruitment of Brg1 to the Pcna, Pdgfα and Ntf3 promoters and affects the promoter region of Brg1 in VSMCs. Immunoprecipitated genomic DNA was am-
pliﬁed by PCR using primers for (A) Pcna-HS1, (B) Pdgfα-HS1 and (C) Ntf3-HS1. Results are expressed as the ratio of the ChIP DNA band density compared to the band density for the
input DNA. **P b 0.01. (D) Effect of H2S on luciferase reporter gene expression in VSMCs. VSMCs were transfected with the plasmid pGL3-basic-BRG1-900, and then treated with
ET-1 and/or NaHS for 24 h, *P b 0.05. Data are presented as mean ± SD of three independent experiments (n = 3).
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deal of evidence supports the fact that Brg1 can induce cell cycle arrest
due to the methylation of CD44 and E-cadherin, or by associating with
p21 which acts as a tumor suppressor in several malignant cell lines
[56–60], the expression of Brg1 is signiﬁcantly upregulated in primary
melanoma, and knockdown of Brg1 abolished the proliferative ability of
melanoma cell lines [61]. These observations imply that Brg1 is not only
a recognized tumor suppressor, but also a tumor initiator, depending on
the tissue or type of carcinoma examined.
Brg1 acts as an essential chromatin modulator during the normal
development of the cardiovascular system and also in a variety of
disease processes in cardiovascular tissues. Brg1 exerts considerable
inﬂuence on growth, differentiation and gene expression in the car-
diovascular system [62]. Brg1 promotes cardiomyocyte proliferation
and differentiation in embryos, and Brg1 usually maintains ‘silenced’
in adults [62]. Expression of Brg1 is re-stimulated by cardiac stress,
which can lead to a pathological switch from α-MHC expression to
β-MHC expression, resulting in cardiac hypertrophy [62]. Speciﬁc
knockdown of Brg1 in cardiomyocytes and VSMCs induced cardiac
outﬂow tract defects, patent ductus arteriosus, thin ventricles and ven-
tricular septal defects [26]. It has been veriﬁed that Brg1, but not Brm, is
necessary for vascular development [25], as the Brg1-containing
SWI/SNF complex interacts with serum response factor (SRF) and
myocardin-related transcription factor A (MRTFA) to facilitate the
expression of SRF-dependent smooth muscle speciﬁc genes [24,26,63].
This evidence suggests that Brg1 plays a more crucial role in the cardio-
vascular system than any other subunit of the SWI/SNF complex, which
is the very reason that we focused on Brg1 in the present study.Our mRNA microarray analysis showed that H2S signiﬁcantly
downregulated the expression of the proliferation-regulating mole-
cule Brg1 and other proliferation-related genes, including Pcna, Ntf3
and Pdgfα, in VSMCs. Furthermore, the expression of the Ntf3, Pcna
and Pdgfα genes and VSMC proliferation correlated positively with
the quantity of Brg1 expressed, as overexpression of Brg1 prevented
the inhibition of VSMC proliferation and downregulation of Pcna,
Ntf3 and Pdgfα induced by H2S. Conversely, knockdown of Brg1
abolished the inhibitory effects of H2S on VSMC proliferation and
Pcna, Ntf3 and Pdgfα expression. These results suggest that Brg1 is
crucial for H2S-induced inhibition of VSMC proliferation.
To further explore how H2S regulates Brg1, a luciferase assay dem-
onstrated that H2S affected the promoter region of the Brg1 gene to
inhibit its expression. In addition, after the overexpression of exogenous
Brg1 containing CMV promoter, H2S was unable to affect Brg1 expres-
sion or inhibit VSMC proliferation, suggesting that H2S regulates Brg1
expression by modifying its promoter region.
It is well known that the proliferation of VSMCs can be induced by
ET-1, via the ET-1 receptors and Ras/Raf/Erk/MAPK signal transduc-
tion pathway [64,65]. Ntf3, Pcna and Pdgfα can also take part in the
proliferation, migration and invasion of VSMCs via the Ras/Erk/MAPK
and PI3K/Akt signal transduction pathway activated by ET-1 [66–76]. As
H2S could inhibit VSMC proliferation via the MAPK pathway [11,12], we
selected three genes, Ntf3, Pcna and Pdgfα, to investigate the possible
mechanisms of transcriptional regulation byH2S at the level of chromatin
structure modiﬁcations. We used DNase I sensitivity analysis to examine
whether chromatin remodeling of theNtf3, Pcna and Pdgfα geneswas as-
sociatedwith the inhibition of VSMCproliferation byH2S. DNase I HSs are
Fig. 5. Brg1 is the critical chromatin modulator involved in the epigenetic control of
VSMC proliferation by H2S. In ET-1-stimulated VSMC proliferation, ET-1 increases
Brg1 expression while H2S diffuses through the cytomembrane and nuclear membrane
to nucleus, where it blocks the induction of Brg1 expression and then disturbs recruit-
ment of Brg1 (the central catalytic subunit of SWI/SNF, an ATP-dependent chromatin
remodeling complex), which leads to regional chromatin remodeling in the promoters
of speciﬁc proliferation-associated genes. Reduced Brg1 activity may induce chromatin
to form a closed conformation, which may restrict the binding of transcription factors,
resulting in decreased gene expression. In other words, H2S can inhibit the expression
of proliferation-associated genes by inducing epigenetic modiﬁcations. Pcna, Ntf3 and
Pdgfα, which function in the MAPK pathway, are affected by reduced Brg1 activity in
response to H2S, which ultimately leads to reduced cell cycle progression possibly
due to downregulation of MAPK pathway activity. Inhibition of VSMC proliferation
due to H2S was closely related to Brg1-induced chromatin remodeling.
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genes.We identiﬁed that threeHSs in Pcna, twoHSs in Pdgfα and twoHSs
in Ntf3were altered by H2S, suggesting that H2S can modify the chroma-
tin structure in the promoter regions or locus control regions of these
genes. The ChIP assay demonstrated that the recruitment of Brg1 to the
HSs in the Ntf3, Pcna and Pdgfα genes was reduced by H2S, indicating
that H2S regulates the expression of the Ntf3, Pcna and Pdgfα genes by
affecting the ability of Brg1 to induce chromatin-remodeling of the pro-
moter regions of these genes. Therefore, Brg1might be a critical regulator
of chromatin-remodeling for theNtf3, Pcna and Pdgfα genes, with respect
to epigenetic modulations induced by H2S.
In summary, this study demonstrates that region-speciﬁc chromatin
remodeling of MAPK signaling pathway-associated genes such as Ntf3,
Pcna and Pdgfα can be regulated by H2S, to inhibit VSMC proliferation,
and that Brg1 acts as a switch to turn these genes ‘on’ in a spatially- and
temporally-speciﬁc manner (Fig. 5). In conclusion, H2S plays a pivotal
role in reprogrammingphysiological andpathophysiological gene expres-
sion patterns via epigenetic mechanisms, at least in part, by modulating
the Brg1-containing SWI/SNF chromatin remodeling complex.Sources of funding
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